Logo image
Impact of a multi-strain L. crispatus-based vaginal synbiotic on the vaginal microbiome: a randomized placebo-controlled trial
Journal article   Open access   Peer reviewed

Impact of a multi-strain L. crispatus-based vaginal synbiotic on the vaginal microbiome: a randomized placebo-controlled trial

Jacques Ravel, Sheri Simmons, Eleni Greenwood Jaswa, Sara Gottfried, Miriam Greene, Susan Kellogg-Spadt, Dirk Gevers and Diane M Harper
NPJ biofilms and microbiomes, v 11(1), 158
09 Aug 2025
PMID: 40783570
url
https://doi.org/10.1038/s41522-025-00788-6View
Published, Version of Record (VoR) Open

Abstract

Adult Candida - isolation & purification Female Gardnerella vaginalis - isolation & purification Humans Lactobacillus crispatus - physiology Microbiota Synbiotics - administration & dosage Vagina - microbiology Young Adult
A clinical trial of a multi-strain vaginal synbiotic (NCT05659745, registered 12/19/2022 at clinicaltrials.gov) led to an optimal vaginal microbiome dominated by L. crispatus (CST I). The synbiotic led to a significant increase in L. crispatus compared to placebo (p < 0.05), and conversion to CST I was significantly higher with the vaginal synbiotic than with placebo (90 vs 11%; p < 0.002). Mechanistically, the synbiotic reduced Gardnerella vaginalis and Candida, clinically important microbes.

Metrics

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Domestic collaboration
Web of Science research areas
Biotechnology & Applied Microbiology
Microbiology
Logo image